Hetta Helal F, Sirag Nizar, Alsharif Shumukh M, Alharbi Ahmad A, Alkindy Tala T, Alkhamali Alanoud, Albalawi Abdullah S, Ramadan Yasmin N, Rashed Zainab I, Alanazi Fawaz E
Division of Microbiology, Immunology and Biotechnology, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Division of Pharmacognosy, Department of Natural Products and Alternative Medicine, Faculty of Pharmacy, University of Tabuk, Tabuk 71491, Saudi Arabia.
Pharmaceuticals (Basel). 2024 Nov 20;17(11):1555. doi: 10.3390/ph17111555.
The rapid progress of antibiotic resistance among bacteria has prompted serious medical concerns regarding how to manage multidrug-resistant (MDR) bacterial infections. One emerging strategy to combat antibiotic resistance is the use of antimicrobial peptides (AMPs), which are amino acid chains that act as broad-spectrum antimicrobial molecules and are essential parts of the innate immune system in mammals, fungi, and plants. AMPs have unique antibacterial mechanisms that offer benefits over conventional antibiotics in combating drug-resistant bacterial infections. Currently, scientists have conducted multiple studies on AMPs for combating drug-resistant bacterial infections and found that AMPs are a promising alternative to conventional antibiotics. On the other hand, bacteria can develop several tactics to resist and bypass the effect of AMPs. Therefore, it is like a battle between the bacterial community and the AMPs, but who will win? This review provides thorough insights into the development of antibiotic resistance as well as detailed information about AMPs in terms of their history and classification. Furthermore, it addresses the unique antibacterial mechanisms of action of AMPs, how bacteria resist these mechanisms, and how to ensure AMPs win this battle. Finally, it provides updated information about FDA-approved AMPs and those that were still in clinical trials. This review provides vital information for researchers for the development and therapeutic application of novel AMPs for drug-resistant bacterial infections.
细菌中抗生素耐药性的迅速发展引发了人们对如何应对多重耐药(MDR)细菌感染的严重医学担忧。一种新兴的对抗抗生素耐药性的策略是使用抗菌肽(AMPs),抗菌肽是作为广谱抗菌分子的氨基酸链,是哺乳动物、真菌和植物固有免疫系统的重要组成部分。抗菌肽具有独特的抗菌机制,在对抗耐药细菌感染方面比传统抗生素更具优势。目前,科学家们已经针对抗菌肽对抗耐药细菌感染进行了多项研究,并发现抗菌肽是传统抗生素的一种有前景的替代品。另一方面,细菌可以发展出多种策略来抵抗和规避抗菌肽的作用。因此,这就像是细菌群落和抗菌肽之间的一场战斗,但谁会获胜呢?这篇综述深入探讨了抗生素耐药性的发展,以及抗菌肽在其历史和分类方面的详细信息。此外,它还阐述了抗菌肽独特的抗菌作用机制、细菌如何抵抗这些机制,以及如何确保抗菌肽赢得这场战斗。最后,它提供了关于美国食品药品监督管理局(FDA)批准的抗菌肽以及仍在临床试验中的抗菌肽的最新信息。这篇综述为研究人员开发用于耐药细菌感染的新型抗菌肽及其治疗应用提供了重要信息。